1/1
Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate‑to‑Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials
media
posted on 2023-02-20, 00:00 authored by Adis Journals on behalf of:, Jonathan I. Silverberg, Charles W. Lynde, Katrina Abuabara, Cataldo Patruno, Anna de Benedetto, Haixing Zhang, Ryan B. Thomas, Gaëlle Bégo-Le Bagousse, Faisal A. Khokhar, Jignesh Vakil, Ainara Rodriguez Marco, Noah A. LevitArticle full text
The above features represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2023
